Clinical reference Biomarker Directory
Back to directory

IL2RA

Emerging

Soluble CD25 (IL2RA) is one of the formal HLH-2004 diagnostic criteria and the most sensitive specialized adult HLH lab test.

Also known as CD25 soluble IL-2 receptor sIL-2R
In plain language

CD25 marks activated immune cells, and its blood-soluble form is one of the key lab tests doctors use to diagnose HLH, a dangerous immune overactivation syndrome. It's also used more generally to gauge lymphoma activity.

Biomarker & context

IL2RA encodes CD25, the alpha subunit of the interleukin-2 receptor; its soluble form (soluble IL-2 receptor, sIL-2R) reflects T-cell activation and is one of the formal diagnostic criteria for hemophagocytic lymphohistiocytosis (HLH).

What it indicates

Elevated soluble CD25 is one of the eight HLH-2004 diagnostic criteria (5 of 8 required for diagnosis) and is considered the most sensitive of the specialized HLH lab tests in adults; it also has roles in lymphoma prognosis and monitoring sarcoidosis activity.

Diagnosis & clinical testing

Measured via serum immunoassay; in HLH workups, it's assessed alongside ferritin, triglycerides, fibrinogen, and other criteria as part of the formal HLH-2004 diagnostic framework, connecting directly to the ferritin and IL-18 discussions in this biomarker set.

Guiding treatment

A markedly elevated soluble CD25 supports HLH diagnosis and treatment initiation (often chemoimmunotherapy per the HLH-94/HLH-2004 protocols) when combined with the other required criteria; in lymphoma, elevated sIL-2R correlates with tumor burden and can be tracked during treatment.

Clinical significance

Also used as a lymphoma prognostic marker and to monitor sarcoidosis disease activity.

References
  1. General hematology reference literature on the HLH-2004 diagnostic criteria and soluble CD25/IL-2 receptor testing.